Insight

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

Photo from Umang Swami/X

Aug 5, 2024, 02:38

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

Umang Swami, Oncologist at Huntsman Cancer Institute, University of Utah, shared a post on X about a recent paper titled “Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States” published in Future Oncology.

Authors: Umang Swami, Agnes Hong, Brandon Diessner, Christopher Young, Scott H Bunner, Bin Xie, Krishnan Ramaswamy, Benjamin Chastek, Nader El Chaar and Sumati Gupta.

“Just in Future Oncology. One of the largest real world studies evaluating TRT trends in nmCRPC found underutilization of NHT even 2 years after approval. ADT and ADT+NSAA remained most common TRT.”

Umang Swami: Evaluating TRT trends in nonmetastatic castration-resistant prostate cancer

Source: Umang Swami/X

ADT ADT+NSAA Agnes Hong Benjamin Chastek Bin Xie Brandon Diessner cancer Christopher Young Future Oncology Huntsman Cancer Institute Krishnan Ramaswamy Nader El Chaar NHT nmCRPC nonmetastatic castration-resistant prostate cancer OncoDaily Oncology Scott H Bunner Sumati Gupta TRT Umang Swami University of Utah

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage